SMS Pharmaceuticals Limited reported Q2FI27 revenue from operations of 316 crores, up 30% over Q2FI26, and expects to exceed FI27 guidance of 15% revenue growth and a 20% EBITDA margin.

3 source passages

In Q2FI27, revenue from operations stood at 316 crores, a growth of 30% over Q2FI26 and 53% over Q1, driven by strong volumes and improving price realization. For FI27, guidance was revenue growth of 15% with an EBITDA margin of 20%. The pricing in our key APIs is expected to remain stable in the near term, and on the back of a strong first half and the outlook for the rest of the year, we now expect to exceed both. On behalf of SMS Pharmaceuticals Limited, that concludes this conference. Open the document at this passage

May 27

Earnings call

Q4 2026 earnings call AI summary on its way

Showing 1–2 of 2 documents